Introduction
The prevalence and number of people with antibodies to hepatitis C virus (anti-HCV) globally are estimated to be 2.8% and 185 million respectively, with two-thirds (124 million) in Asia. 1 HCV genotype distribution varies greatly in the Asian regions, with estimated populations of 54, 12, 48, 7.5, and 9.7 million, respectively, for HCV genotype 1 (HCV-1), HCV-2, HCV-3, HCV-4, and HCV-6, respectively (Table 1) . 2 More than 80% of Asian persons infected with HCV have a more favorable host genotype (either interleukin-28B (IL28B) rs12979860 CC versus CT or TT or IL28B rs8099917 TT versus GT or GG). These innate immune genotypes are associated with a higher rate of sustained virological response (SVR) to treatment with pegylated interferon and ribavirin. For example, 80% of Asian HCV gentotype-1 patients with lower baseline viral loads (LVL) and the IL28B CC host genotype can expect to achieve an SVR after a 24-week course of peginterferon/ribavirin.
Peginterferon/Ribavirin for Asian Patients
For Asian patients infected by HCV genotype 1 or 4, the SVR rates in response to peginterferon/ribavirin for 48 weeks and 24 weeks are 60% and 75%, whereas for patients with genotype 2 or 3 virus the rates of SVR rise to 80% and 90% respectively. 5 With a strategy of response-guided therapy 
Perspective of Directly-Acting Antiviral Agent in Asia
The progress of directly-acting antiviral agent (DAA) in HCV treatment is moving from interferon-containing regimens in 2011 to interferon-free regimens, which are the current standard of care in most Western countries. Table 2 and Figure 1 demonstrate the timeline and expected indications of DAA regimens in Asia-Pacific countries. Unfortunately, the variety and uncertainty of the timeline for DAAs in Asia-Pacific make it difficult to develop a universal HCV practice guideline appropriate for the whole Asian population.
Interferon-Containing Regimens
The first wave of NS3/4A protease inhibitors, boceprevir and telaprevir, in combination with peginterferon/ribavirin for between 24 and 48 weeks based on RGT, was approved for HCV-1 treatment-na€ ıve and experienced patients in several Asian countries. However, adding a first generation protease inhibitor had no benefit for HCV-1 treatment-na€ ıve patients with LVL and RVR compared with a 24-week course of peginteferon and ribavirin. 10 Japan approved 24-week telaprevir triple therapy for HCV-2 in September 2014. Simeprevir, a second wave protease inhibitor, has recently been approved in Japan and Australia, for use in concert with peginterferon and ribavirin for HCV genotype 1 and 4 patients, both treatment-naive and treatment experienced.
Sofosbuvir, a pangenotypic NS5B nucleotide polymerase inhibitor with high efficacy (SVR rates > 90%) has recently received approval in Australia and Macau for use in conjunction with with pegylated interferon and ribavirin for 12 week course of therapy in HCV genotypes 1, 3-6.
Daclatasvir, a NS5A inhibitor, in combination with peginterferon/ribavirin based on RGT, was approved for HCV-4 patients in Europe in October 2014.
Interferon-Free Regimens
Sofosbuvir plus a weight-based dose of ribavirin, was approved for all HCV genotypes in Australia and 2014, thereby becoming the first interferon-free regimen approved for use in Asia. A 12-week and 24-week regimen is recommended for HCV-2 and HCV-3 patients, respectively, with SVR rates of > 90%. However, 24 weeks of sofosbuvir/ribavirin, with SVR rate of 60% to 70% for HCV-1 patients, is an alternative recommendation for interferon-ineligible patients.
Instead, 12 weeks for sofosbuvir plus simeprevir, with high SVR rates (> 90%) in phase 2 COSMOS trial, is an off-label recommendation for HCV-1/interferon-ineligible patients.
The first approved interferon-free regimen for HCV-1b, 24-week daclatasvir plus asunaprevir (NS3/4A protease inhibitor), was approved in Japan in July 2014 for interferon-ineligible/intolerant and treatment-experienced patients with SVR rates of 85% to 90%. Sofosbuvir plus daclatasvir with/without ribavirin for 12 to 24 weeks was approved for na€ ıve or experienced HCV1-4 patients in Europe in August 2014. A fixed-dose combination of sofosbuvir/ledipasvir, a NS5A inhibitor, for 8 to 12 weeks with SVR rates of > 92% for HCV-1 treatmentna€ ıve and experienced patients was approved in the United States in October 2014. Both regimens are expected to be available in Asia before 2016. Recently, two fixed-dose combinations, 12-week daclatasvir/asunaprevir/BMS-791325 (NS5B nonnucleoside analogue) and 12-week grazooprevir (NS3/4A protease inhibitor)/elbasvir (NS5A inhibitor) could attain SVR rates of > 90% for HCV-1 and HCV1-6, respectively. The phase 3 studies are ongoing now.
HCV Practice Recommendation in Asia-Pacific
Lacking a one-size-fits-all regimen increases HCV treatment complexity and barriers. The current recommendations should be based on the availability, indication, and cost-effectiveness of DAAs in Asia (Table 2) .
Treatment-na€ ıve interferon-eligible patients without DAA available (Fig. 2a) The treatment algorithm is based on the 2012 Asian Pacific Association for the Study of the Liver (APASL) HCV practice guideline 6 with modification: treatment should be stopped for HCV-1 patients with HCV RNA decline < 1 log at W4 (interferonnonresponsiveness) 11 and for HCV-2/3 patients without EVR.
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Treatment-na€ ıve interferon-eligible patients with DAA available (Fig. 2b) 1. HCV-1, 4, 6: DAA-containing regimens for patients with high viral load (HVL) and IL28B-non-CC genotype. Either peginterferon/ribavirin dual therapy or DAAcontaining regimens for patients of LVL/IL28B-CC without rapid virological response (RVR), LVL/IL28B-non-CC, or HVL/IL28-CC, based on cost-effectiveness. Twenty-four weeks of peginterferon/ribavirin for patients with LVL and IL28B-CC genotype if only boceprevir/ peginterferon/ribavirin, telaprevir/peginterferon/ribavirin, simeprevir/peginterferon/ribavirin, or daclatasvir/ peginterferon/ribavirin are available.
HCV-2/3:
Sixteen to 24 weeks of RGT with peginterferon/ribavirin for noncirrhotic patients.
DAA-containing regimens for cirrhotic patients, and for non-RVR patients if cost-effective. Treatment-experienced interferon-eligible patients without DAA available (Fig. 2c) Forty-eight weeks of peginterferon/ribavirin for HCV-1,4,6 prior relapsers with IL28B-CC genotype; 24 weeks of peginterferon/ribavirin for HCV-2/3 prior relapsers. Treatment should be stopped for patients without EVR and for HCV-1 with HCV RNA decline < 1 log at W4. Deferring treatment for all prior partial/null responders and for HCV-1 IL28B-non-CC patients.
Treatment-experienced interferon-eligible patients with DAA available (Fig. 2d) DAA-containing regimens for all patients. Alternatively, 48 weeks of peginterferon/ribavirin for HCV-1,4,6 prior relapsers with IL28B-CC genotype, and 24 weeks of peginterferon/ribavirin for HCV-2/3 prior relapsers, if cost-effective.
Interferon-ineligible/intolerant patients
Interferon-free DAA regimens according to viral genotypes.
Conclusion
In the emerging era of DAA, treatment should weigh the benefit/risk and cost-effectiveness, especially in lower socioeconomic areas of Asia. Before the availability of interferonfree DAA regimens, peginterferon/ribavirin will hang around years in a number of Asian countries. n
